America's Health Rankings, United Health Foundation Logo

Cervical Cancer Screening
Cervical Cancer Screening in Mississippi

Explore national- and state-level data for hundreds of health, environmental and socioeconomic measures, including background information about each measure. Use features on this page to find measures; view subpopulations, trends and rankings; and download and share content.

How to use this page

Mississippi Value:


Percentage of women ages 21-44 who reported receiving a Pap smear within the past three years

Mississippi Rank:


Cervical Cancer Screening in depth:

Explore Population Data:

General Population

Cervical Cancer Screening by State

Percentage of women ages 21-44 who reported receiving a Pap smear within the past three years

Cervical Cancer Screening Trends

Percentage of women ages 21-44 who reported receiving a Pap smear within the past three years

Trend: Cervical Cancer Screening in Mississippi, United States, 2023 Health Of Women And Children Report

Percentage of women ages 21-44 who reported receiving a Pap smear within the past three years

United States

 CDC, Behavioral Risk Factor Surveillance System

View All Populations
Compare States

About Cervical Cancer Screening

US Value: 77.1%

Top State(s): Mississippi: 85.2%

Bottom State(s): Alaska: 67.9%

Definition: Percentage of women ages 21-44 who reported receiving a Pap smear within the past three years

Data Source and Years: CDC, Behavioral Risk Factor Surveillance System, 2020

Suggested Citation: America's Health Rankings analysis of CDC, Behavioral Risk Factor Surveillance System, United Health Foundation,, accessed 2023.

Cervical cancer is preventable with screening tests and vaccines, and highly treatable when caught early. Increased screening in the form of routine Pap tests has contributed to significant declines in cervical cancer mortality over the past 40 years. In 2019, an estimated 18.3 million women were not up-to-date on their cervical cancer screening. Screening rates declined sharply during the COVID-19 pandemic, but have gradually returned to near baseline since clinics resumed routine screening. 

The American Cancer Society estimates that there will be approximately 14,000 new cases of invasive cervical cancer diagnosed in 2023, and 4,300 cervical cancer deaths. The main cause of cervical cancer is the human papillomavirus (HPV), a group of common viruses transmitted during sexual contact. It is estimated that nearly all sexually active people will get HPV at some point during their lifetimes, but recommended HPV vaccinations effectively protect against and reduce rates of cancer-causing strains. 

The Centers for Disease Control and Prevention (CDC) estimates that the medical cost of cervical cancer care in the U.S. was $2.3 billion in 2020. Early-stage cervical cancer is much less expensive to treat. Increasing cervical cancer screening rates can reduce health care costs and save lives.

According to America’s Health Rankings data, the prevalence of cervical cancer screening is higher among:

  • Non-Hispanic Black, non-Hispanic white and multiracial women compared with Asian women. 
  • Women ages 25-44 compared with women ages 21-24.
  • Women with some post-high school education and college graduates compared with those with less than a high school education.
  • Women with an annual household income of $50,000 or more compared with those with incomes less than $50,000.

Additional studies have found that rates of cervical cancer screening are higher among:

  • Women living in metropolitan areas compared with those in non-metropolitan areas.
  • Women with a usual source of care compared with those who had none or used emergency departments for care.
  • Women with insurance compared with uninsured women. Women with Medicaid coverage also have low screening rates.
  • Heterosexual women compared with lesbian women.

The CDC recommends regular screening via Pap and/or HPV tests, as well as HPV vaccination in early adolescence to prevent cervical cancer. The U.S. Preventive Services Task Force (USPSTF) strongly recommends women ages 21-29 get a Pap test every three years. For women ages 30-65, the USPSTF recommends either: a) a Pap test every three years, b) HPV testing every five years, or c) a combined HPV and Pap test every five years. Women with HIV have a higher risk of cervical cancer compared to women without HIV, and should follow the screening recommendations in the federally approved clinical Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV.

The Community Guide lists several interventions that are effective in increasing cervical cancer screening, including:

Additional strategies to improve cervical cancer screening rates among women include:

  • Increasing awareness of cervical cancer and the benefits of screening.
  • Having health care providers recommend and/or educate patients on screening: Direct communication between patient and provider increases screening and can be effective among populations of women whose cultural beliefs and practices may disagree with screening.

Healthy People 2030 aims to increase the proportion of women ages 21-65 who receive cervical cancer screening. 


Dorsainvil, Merlyn A. “Increasing Cervical Cancer Screening in Underserved Populations.” Journal of Christian Nursing 34, no. 3 (July 2017): 152–58.

Hernández-Ramírez, Raúl U, Meredith S Shiels, Robert Dubrow, and Eric A Engels. “Cancer Risk in HIV-Infected People in the USA from 1996 to 2012: A Population-Based, Registry-Linkage Study.” The Lancet HIV 4, no. 11 (November 2017): e495–504.

Miller, Maureen J., Lanfang Xu, Jin Qin, Erin E. Hahn, Quyen Ngo-Metzger, Brian Mittman, Devansu Tewari, et al. “Impact of COVID-19 on Cervical Cancer Screening Rates Among Women Aged 21–65 Years in a Large Integrated Health Care System — Southern California, January 1–September 30, 2019, and January 1–September 30, 2020.” MMWR. Morbidity and Mortality Weekly Report 70, no. 4 (January 29, 2021): 109–13.

Sabatino, Susan A., Trevor D. Thompson, Mary C. White, Jean A. Shapiro, Tainya C. Clarke, Jennifer M. Croswell, and Lisa C. Richardson. “Cancer Screening Test Use?U.S., 2019.” American Journal of Preventive Medicine 63, no. 3 (September 2022): 431–39.

Suk, Ryan, Young-Rock Hong, Suja S. Rajan, Zhigang Xie, Yenan Zhu, and Jennifer C. Spencer. “Assessment of US Preventive Services Task Force Guideline–Concordant Cervical Cancer Screening Rates and Reasons for Underscreening by Age, Race and Ethnicity, Sexual Orientation, Rurality, and Insurance, 2005 to 2019.” JAMA Network Open 5, no. 1 (January 18, 2022): e2143582.

Tracy, J. Kathleen, Alison D. Lydecker, and Lynda Ireland. “Barriers to Cervical Cancer Screening Among Lesbians.” Journal of Women’s Health 19, no. 2 (February 2010): 229–37.

Current Reports

America’s Health Rankings builds on the work of the United Health Foundation to draw attention to public health and better understand the health of various populations. Our platform provides relevant information that policymakers, public health officials, advocates and leaders can use to effect change in their communities.

We have developed detailed analyses on the health of key populations in the country, including women and children, seniors and those who have served in the U.S. Armed Forces, in addition to a deep dive into health disparities across the country.